System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Cécile Guillemet is an expert in Oncology at Centre Henri Becquerel (France). Cécile Guillemet has authored 112 publications, the most recent in 2026, and is an investigator in 18 clinical trials, 3 of them ongoing. SLR score: 462 (community average: 125). How the SLR is computed.

LeadR Profile

Cécile Guillemet Centre Henri Becquerel France
462 ScienceLeadR Reputation 462

Unlock

Register Login
Network Map

Oncology

Subspecialties: Gynecology - Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2008 - 2026
Source: PubMed

Centre Henri Becquerel

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 112

Citations

Citations: 7 671 1st author: 0 Last author: 0 Unique author: 0

Main journals

Ann Oncol 21
J Clin Oncol 18
Eur J Cancer 10
Gynecol Oncol 6
Int J Gynecol Cancer 5

Best Journals

Ann Oncol 11
J Clin Oncol 5
Lancet Oncol 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Head & Neck and Shoulder Desmoid-Type Fibromatosis: Presentation and Natural History of These Ultra-Rare Locations.
PMID 42905937 — fibromatosis, aggressive, natural history, pain, neoplasms, history		Cancer Med20260
Clinical outcomes and prognostic factors in advanced high-grade platinum-resistant ovarian carcinoma: evidence from the ESME real-world cancer database.
PMID 42660771 — progression-free survival, paclitaxel, ovary, genital neoplasms, female, doxorubicin, neoplasms, multiple chronic conditions, bevacizumab, drug therapy, ovarian neoplasms, prognosis, chemotherapy		Int J Gynecol Cancer20260
Overall survival of patients with localized soft tissue sarcoma treated with or without adjuvant chemotherapy (DEEPSARC): a real world nationwide retrospective cohort study in France.
PMID 42291149 — registries, cohort studies, drug therapy, sarcoma, chemotherapy, adjuvant, work, therapeutics, tissues, aids-related complex, chemotherapy		EClinicalMedicine20263
Characteristics and outcome of intra-abdominal desmoid-type fibromatosis.
PMID 42173035 — fibromatosis, aggressive, neoplasms		Eur J Surg Oncol20260
Optimising rare tumour risk syndromes care: clinical insights and the PREVENTABLE socioeconomic framework.
PMID 42129296 — genetics, medical		Eur J Hum Genet20261

Clinical Studies 18

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 2 7
N/A 6
Phase 3 5

By status:

Completed 9
Recruiting 5
Active not recruiting 1
Suspended 1
Terminated 1
Unknown 1

By type:

Interventional 15
Observational 3

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 1
multicentric5to9 0
multicentricup10 14

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Interest of post operative chemotherapy in patients with localized uterine leiomyosarcoma suspected to have a high risk of relapse based on a biologic test performed on the tumor
2023-506350-21-00 — leiomyosarcoma, neoplasms, classification, drug therapy, chemotherapy, adjuvant, chemotherapy		Phase 2Recruiting2025
Interest of Post operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
NCT06524583 — leiomyosarcoma, uterus, doxorubicin, drug therapy, chemotherapy, adjuvant, trabectedin, chemotherapy		Phase 2Recruiting2025
Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)
NCT04921553 — registries, genes, quality of life, data collection, proto-oncogene proteins c-sis, neoplasms, gene rearrangement, gene fusion, therapeutics, mutation		N/ARecruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS